EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis

Chen,Long; Zhou,Yongchun; Tang,Xiaoxia; Yang,Conghui; Tian,Yadong; Xie,Ran; Chen,Ting; Yang,Jiapeng; Jing,Mingwei; Chen,Fukun; Wang,Chun; Sun,Hua; Huang,Yunchao

doi:10.3892/ijo.2018.4626

EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis

Authors:
- Long Chen
- Yongchun Zhou
- Xiaoxia Tang
- Conghui Yang
- Yadong Tian
- Ran Xie
- Ting Chen
- Jiapeng Yang
- Mingwei Jing
- Fukun Chen
- Chun Wang
- Hua Sun
- Yunchao Huang
View Affiliations

Affiliations: Department of PET/CT Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, Yunnan 650118, P.R. China, Tumor Research Institute of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, Yunnan 650118, P.R. China, Department of Pharmacy, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, P.R. China, Department of Nuclear Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, Yunnan 650118, P.R. China, Department of Thoracic Surgery I, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, Yunnan 650118, P.R. China, Department of Ultrasonic, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, Yunnan 650118, P.R. China
Published online on: November 6, 2018 https://doi.org/10.3892/ijo.2018.4626
Pages: 370-380

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

[18F]fluoro‑2‑deoxyglucose (FDG) positron emission tomography (PET)‑computed tomography (CT) is a functional imaging modality based on glucose metabolism. The association between the maximum standardized uptake value (SUVmax) from 18F‑FDG PET‑CT scanning and epidermal growth factor receptor (EGFR) mutation status has, to the best of our knowledge, not previously been fully elucidated, and the potential mechanisms by which EGFR mutations alter FDG uptake are largely unknown. A total of 157 patients who were pathologically diagnosed with non‑small cell lung cancer (NSCLC) who underwent EGFR mutation testing and PET‑CT pretreatment between June 2015 and October 2017 were retrospectively analyzed. χ2 and univariate analyses were performed to identify the contributors to EGFR mutation. The receiver operating characteristic (ROC) curve was analyzed, and the area under the curve (AUC) was calculated. Glucose transporter 1 (GLUT1) and NADPH oxidase 4 (NOX4) expression, and reactive oxygen species (ROS) activity were detected in the A549 (wild‑type), PC‑9 (EGFR mutation‑positive, EGFR exon 19del) and NCI‑H1975 (EGFR mutation‑positive, combined with L858R and T790M substitution) cell lines. A total of 109 patients who met the criteria were enrolled, and 63 of those tested as EGFR mutation‑positive. The SUVmax values were significantly lower in patients with EGFR mutations (mean, 6.52±0.38) compared with in patients with wild‑type EGFR (mean, 9.37±0.31; P<0.001). Using univariate analysis, EGFR mutation status was significantly associated with sex, smoking status, tumor histology and SUVmax of the primary tumor. In the multivariate analysis, smoking status (never‑smoking), histopathology (adenocarcinoma) and SUVmax (≤9.91) were the statistically significant predictors of EGFR mutations. ROC curve analysis identified that the SUVmax cut‑off point was 9.92, for which the AUC was 0.75 (95% confidence interval, 0.68‑0.83). Reverse transcription‑polymerase chain reaction indicated that the GLUT1 mRNA decreased in the PC‑9 and NCI‑H1975 cell lines compared with the A549 cell line (0.82±0.07 and 0.72±0.04 vs. 0.98±0.04, respectively; P<0.05) and decreased ROS activity was observed in the PC‑9 cell line. Furthermore, the expression of NOX4 mRNA decreased by 20% in PC‑9 (P<0.01) and by 14% (P<0.05) in NCI‑H1975 cells. In addition, NOX4 protein expression decreased by 13% in PC‑9 and by 16% in NCI‑H1975 cells (both P<0.05) compared with the A549 cell line. The SUVmax could be considered to effectively predict EGFR mutation status of patients with NSCLC, and the EGFR mutation status may alter FDG uptake partially via the NOX4/ROS/GLUT1 axis.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH and Lee KH; Community of Population-Based Regional Cancer Registries: Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 49:292–305. 2017. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D and Jemal A: Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 65:457–480. 2015. View Article : Google Scholar : PubMed/NCBI
5	Janssen S, Käsmann L, Rudat V and Rades D: Stereotactic body radiation therapy (SBRT) for recurrent non-small cell lung cancer (NSCLC). Anticancer Res. 36:825–828. 2016.PubMed/NCBI
6	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
7	Santarpia M, Altavilla G, Salazar MF, Magri I, Pettineo G, Benecchi S and Rosell R: Tyrosine kinase inhibitors for non-small-cell lung cancer: Finding patients who will be responsive. Expert Rev Respir Med. 5:413–424. 2011. View Article : Google Scholar : PubMed/NCBI
8	Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao D and Habib AA: Ligand-independent EGFR signaling. Cancer Res. 75:3436–3441. 2015. View Article : Google Scholar : PubMed/NCBI
9	Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, et al: Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res. 69:8341–8348. 2009. View Article : Google Scholar : PubMed/NCBI
10	Kong FM, Ten Haken RK, Schipper M, Frey KA, Hayman J, Gross M, Ramnath N, Hassan KA, Matuszak M, Ritter T, et al: Effect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: A phase 2 clinical trial. JAMA Oncol. 3:1358–1365. 2017. View Article : Google Scholar : PubMed/NCBI
11	Levine M and Julian J: Imaging: PET-CT imaging in non-small-cell lung cancer. Nat Rev Clin Oncol. 6:619–620. 2009. View Article : Google Scholar : PubMed/NCBI
12	Na II, Byun BH, Kang HJ, Cheon GJ, Koh JS, Kim CH, Choe DH, Ryoo BY, Lee JC, Lim SM, et al: ¹⁸F-fluoro-2-deoxyglucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer. Clin Cancer Res. 14:2036–2041. 2008. View Article : Google Scholar : PubMed/NCBI
13	Kobe C, Scheffler M, Holstein A, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Dietlein M, et al: Predictive value of early and late residual ¹⁸F-fluorodeoxyglucose and ¹⁸F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging. 39:1117–1127. 2012. View Article : Google Scholar : PubMed/NCBI
14	Horiuchi C, Tsukuda M, Taguchi T, Ishiguro Y, Okudera K and Inoue T: Correlation between FDG-PET findings and GLUT1 expression in salivary gland pleomorphic adenomas. Ann Nucl Med. 22:693–698. 2008. View Article : Google Scholar : PubMed/NCBI
15	Grabellus F, Nagarajah J, Bockisch A, Schmid KW and Sheu SY: Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med. 37:121–127. 2012. View Article : Google Scholar : PubMed/NCBI
16	Prata C, Maraldi T, Fiorentini D, Zambonin L, Hakim G and Landi L: Nox-generated ROS modulate glucose uptake in a leukaemic cell line. Free Radic Res. 42:405–414. 2008. View Article : Google Scholar : PubMed/NCBI
17	Prata C, Maraldi T, Zambonin L, Fiorentini D, Hakim G and Landi L: ROS production and Glut1 activity in two human megakaryocytic cell lines. Biofactors. 20:223–233. 2004. View Article : Google Scholar
18	Lo YM: The amplification refractory mutation system. Methods Mol Med. 16:61–69. 1998.PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔC(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
20	Weyemi U, Lagente-Chevallier O, Boufraqech M, Prenois F, Courtin F, Caillou B, Talbot M, Dardalhon M, Al Ghuzlan A, Bidart JM, et al: ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene. 31:1117–1129. 2012. View Article : Google Scholar :
21	Waris G, Turkson J, Hassanein T and Siddiqui A: Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: Role of STAT-3 in HCV replication. J Virol. 79:1569–1580. 2005. View Article : Google Scholar : PubMed/NCBI
22	Kodama R, Kato M, Furuta S, Ueno S, Zhang Y, Matsuno K, Yabe-Nishimura C, Tanaka E and Kamata T: ROS-generating oxidases Nox1 and Nox4 contribute to oncogenic Ras-induced premature senescence. Genes Cells. 18:32–41. 2013. View Article : Google Scholar
23	Lara-Guerra H, Waddell TK, Salvarrey MA, Joshua AM, Chung CT, Paul N, Boerner S, Sakurada A, Ludkovski O, Ma C, et al: Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J Clin Oncol. 27:6229–6236. 2009. View Article : Google Scholar : PubMed/NCBI
24	Sunaga N, Tomizawa Y, Yanagitani N, Iijima H, Kaira K, Shimizu K, Tanaka S, Suga T, Hisada T, Ishizuka T, et al: II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer. 56:383–389. 2007. View Article : Google Scholar : PubMed/NCBI
25	Liu A, Han A, Zhu H, Ma L, Huang Y, Li M, Jin F, Yang Q and Yu J: The role of metabolic tumor volume (MTV) measured by [¹⁸F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer. Oncotarget. 8:33736–33744. 2017.PubMed/NCBI
26	Guan J, Xiao NJ, Chen M, Zhou WL, Zhang YW, Wang S, Dai YM, Li L, Zhang Y, Li QY, et al: ¹⁸F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer. Medicine (Baltimore). 95:e44212016. View Article : Google Scholar
27	Minamimoto R, Jamali M, Gevaert O, Echegaray S, Khuong A, Hoang CD, Shrager JB, Plevritis SK, Rubin DL, Leung AN, et al: Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative ¹⁸F FDG-PET/CT metrics. Oncotarget. 8:52792–52801. 2017. View Article : Google Scholar : PubMed/NCBI
28	Takamochi K, Mogushi K, Kawaji H, Imashimizu K, Fukui M, Oh S, Itoh M, Hayashizaki Y, Ko W, Akeboshi M, et al: Correlation of EGFR or KRAS mutation status with ¹⁸F-FDG uptake on PET-CT scan in lung adenocarcinoma. PLoS One. 12:e01756222017. View Article : Google Scholar
29	Caicedo C, Garcia-Velloso MJ, Lozano MD, Labiano T, Vigil Diaz C, Lopez-Picazo JM, Gurpide A, Zulueta JJ, Richter Echevarria JA and Perez Gracia JL: Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 41:2058–2065. 2014. View Article : Google Scholar : PubMed/NCBI
30	Yoshida T, Tanaka H, Kuroda H, Shimizu J, Horio Y, Sakao Y, Inaba Y, Iwata H, Hida T and Yatabe Y: Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs. Lung Cancer. 100:14–19. 2016. View Article : Google Scholar : PubMed/NCBI
31	Lee SM, Bae SK, Jung SJ and Kim CK: FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: A retrospective analysis of 206 patients. Clin Nucl Med. 40:950–958. 2015. View Article : Google Scholar : PubMed/NCBI
32	Cho A, Hur J, Moon YW, Hong SR, Suh YJ, Kim YJ, Im DJ, Hong YJ, Lee HJ, Kim YJ, et al: Correlation between EGFR gene mutation, cytologic tumor markers, ¹⁸F-FDG uptake in non-small cell lung cancer. BMC Cancer. 16:2242016. View Article : Google Scholar
33	Ko KH, Hsu HH, Huang TW, Gao HW, Shen DH, Chang WC, Hsu YC, Chang TH, Chu CM, Ho CL, et al: Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. Eur J Nucl Med Mol Imaging. 41:1889–1897. 2014. View Article : Google Scholar : PubMed/NCBI
34	Putora PM, Früh M and Müller J: FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma. Respirology. 18:734–735. 2013. View Article : Google Scholar : PubMed/NCBI
35	Hogan A, Heyner S, Charron MJ, Copeland NG, Gilbert DJ, Jenkins NA, Thorens B and Schultz GA: Glucose transporter gene expression in early mouse embryos. Development. 113:363–372. 1991.PubMed/NCBI
36	Liemburg-Apers DC, Willems PH, Koopman WJ and Grefte S: Interactions between mitochondrial reactive oxygen species and cellular glucose metabolism. Arch Toxicol. 89:1209–1226. 2015. View Article : Google Scholar : PubMed/NCBI
37	Fiorentini D, Prata C, Maraldi T, Zambonin L, Bonsi L, Hakim G and Landi L: Contribution of reactive oxygen species to the regulation of Glut1 in two hemopoietic cell lines differing in cytokine sensitivity. Free Radic Biol Med. 37:1402–1411. 2004. View Article : Google Scholar : PubMed/NCBI
38	Gorrini C, Harris IS and Mak TW: Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 12:931–947. 2013. View Article : Google Scholar : PubMed/NCBI
39	Kawano Y, Iwama E, Tsuchihashi K, Shibahara D, Harada T, Tanaka K, Nagano O, Saya H, Nakanishi Y and Okamoto I: CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment. Lung Cancer. 113:72–78. 2017. View Article : Google Scholar : PubMed/NCBI
40	Jafari N, Kim H, Park R, Li L, Jang M, Morris AJ, Park J and Huang C: CRISPR-Cas9 mediated NOX4 knockout inhibits cell proliferation and invasion in HeLa cells. PLoS One. 12:e01703272017. View Article : Google Scholar : PubMed/NCBI
41	Crosas-Molist E, Bertran E, Rodriguez-Hernandez I, Herraiz C, Cantelli G, Fabra À, Sanz-Moreno V and Fabregat I: The NADPH oxidase NOX4 represses epithelial to amoeboid transition and efficient tumour dissemination. Oncogene. 36:3002–3014. 2017. View Article : Google Scholar :
42	Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, Scarpulla RC and Chandel NS: Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab. 1:409–414. 2005. View Article : Google Scholar : PubMed/NCBI
43	Jung KH, Lee JH, Thien Quach CH, Paik JY, Oh H, Park JW, Lee EJ, Moon SH and Lee KH: Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1alpha activation. J Nucl Med. 54:2161–2167. 2013. View Article : Google Scholar : PubMed/NCBI
44	Orcutt KP, Parsons AD, Sibenaller ZA, Scarbrough PM, Zhu Y, Sobhakumari A, Wilke WW, Kalen AL, Goswami P, Miller FJ Jr, et al: Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4. Cancer Res. 71:3932–3940. 2011. View Article : Google Scholar : PubMed/NCBI
45	Sobhakumari A, Schickling BM, Love-Homan L, Raeburn A, Fletcher EV, Case AJ, Domann FE, Miller FJ Jr and Simons AL: NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells. Toxicol Appl Pharmacol. 272:736–745. 2013. View Article : Google Scholar : PubMed/NCBI
46	Zhou Y, Yang Y, Yang C, Chen Y, Yang C, Du Y, Zhao G, Guo Y, Ye L and Huang Y: Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China. Oncotarget. 8:15023–15033. 2017.PubMed/NCBI
47	Lan Q, He X, Shen M, Tian L, Liu LZ, Lai H, Chen W, Berndt SI, Hosgood HD, Lee KM, et al: Variation in lung cancer risk by smoky coal subtype in Xuanwei. China Int J Cancer. 123:2164–2169. 2008. View Article : Google Scholar
48	Mumford JL, He XZ, Chapman RS, Cao SR, Harris DB, Li XM, Xian YL, Jiang WZ, Xu CW, Chuang JC, et al: Lung cancer and indoor air pollution in Xuan Wei, China. Science. 235:217–220. 1987. View Article : Google Scholar : PubMed/NCBI
49	Pieper U, Eswar N, Davis FP, Braberg H, Madhusudhan MS, Rossi A, Marti-Renom M, Karchin R, Webb BM, Eramian D, et al: MODBASE: A database of annotated comparative protein structure models and associated resources. Nucleic Acids Res. 34:D291–D295. 2006. View Article : Google Scholar :